FSH glycosylation variant D3N
View Patent ↗FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.
1. A mutant Follicle Stimulating Hormone (“FSH”), wherein the β-subunit comprises SEQ ID NO:3 and wherein the α-subunit comprises SEQ ID NO: 4.
2. The mutant FSH of claim 1 , wherein any one of from 0 to 6 asparagine (N) residues are glycosylated.
3. The mutant FSH of claim 1 , wherein N3 of NO: 4 is glycosylated.
4. A method of producing an FSH mutant comprising:
(a) providing a cell comprising a nucleic acid encoding SEQ ID NO:4 and a second nucleic acid encoding SEQ ID NO:3; and
(b) culturing the cell under conditions that allow expression of the first and second nucleic acids.
5. The method of claim 4 , wherein the cell is capable of glycosylating protein.
6. The method of claim 5 , wherein the cell comprises a single vector which comprises a nucleic acid encoding SEQ ID NO:4 and a nucleic acid encoding SEQ ID NO:3.
7. The method of claim 5 , wherein the cell comprises a vector comprising a nucleic acid encoding SEQ ID NO:4 and a second vector comprising a nucleic acid encoding SEQ ID NO:3.
8. A pharmaceutical composition comprising the mutant FSH of claim 1 and a pharmaceutically acceptable carrier or excipient.
9. A method of treating an infertile mammal, comprising administering to a mammal in need thereof the pharmaceutical composition of claim 8 .
10. A method of stimulating folliculogenesis in a mammal, comprising administering to a mammal in need thereof the pharmaceutical composition of claim 8 .
11. A method of inducing ovarian hyperstimulation in a mammal, comprising administering to a mammal in need thereof the pharmaceutical composition of claim 8 .